ATNF — 180 Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00
- $2.02m
- $2.13m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -0.091 | -10.9 | -20.3 | -38.7 | -19.9 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | -1.37 | 4.18 | 9.07 | 24.7 | 11.3 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.014 | 2.73 | -8.2 | 2.72 | -0.014 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -1.45 | -3.87 | -19.4 | -12.1 | -10.9 |
Capital Expenditures | — | 0 | — | — | — |
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 108 | 14.5 | 0 | — | — |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 108 | 14.5 | 0 | — | — |
Financing Cash Flow Items | 0.74 | -0.138 | -2.06 | -1.01 | -0.06 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -107 | -8.73 | 25.4 | 10.9 | 5.91 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.276 | 2.03 | 6.12 | -1.25 | -4.99 |